The Challenge of Helicobacter Pylori Resistance to Antibiotics: the Comeback of Bismuth-based Quadruple Therapy

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2012 Mar 17

PMID 22423259

Citations 34

Authors

Francis Megraud

Affiliations

Soon will be listed here.

Abstract

A proton-pump inhibitor (PPI), clarithromycin-based, triple therapy has been the recommended treatment for Helicobacter pylori eradication for the past 15 years. Due to a steady increase in H. pylori resistance to clarithromycin, this triple clarithromycin-based treatment has become progressively less efficacious. Several approaches are available to address this situation: one is to test for clarithromycin resistance so that this triple clarithromycin-based regimen is given only to those who will benefit; a second is to prescribe the drugs sequentially, beginning with amoxicillin and a PPI followed by clarithromycin and metronidazole, again with a PPI or the four drugs prescribed concomitantly; a third alternative is to use bismuth-based quadruple therapy, PPI plus a standardized three-in-one capsule, bismuth subcitrate potassium, metronidazole, and tetracycline (BMT, sold under licence as Pylera®). The advantages of these different approaches are reviewed, including the relevance of BMT three-in-one capsule in clinical practice.

Citing Articles

Efficacy and safety of low-dose tetracycline, amoxicillin quadruple therapy in infection: A retrospective single center study.

Zhao Y, Wang X, Zhu M, Chen A, Zhang D, Du Q World J Gastroenterol. 2024; 30(39):4295-4304.

PMID: 39492823 PMC: 11525849. DOI: 10.3748/wjg.v30.i39.4295.

Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for infection between 2013 and 2021: results from the European registry on management (Hp-EuReg).

Olmedo L, Calvet X, Gene E, Bordin D, Voynovan I, Castro-Fernandez M Gut. 2024; 74(1):15-25.

PMID: 39461739 PMC: 11671959. DOI: 10.1136/gutjnl-2024-332804.

Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice.

Roberts L, Issa P, Sinnathamby E, Granier M, Mayeux H, Eubanks T Life (Basel). 2022; 12(12).

PMID: 36556402 PMC: 9785457. DOI: 10.3390/life12122038.

Review on Plant-Based Management in Combating Antimicrobial Resistance - Mechanistic Perspective.

Arip M, Selvaraja M, R M, Tan L, Leong M, Tan P Front Pharmacol. 2022; 13:879495.

PMID: 36249774 PMC: 9557208. DOI: 10.3389/fphar.2022.879495.

Molecular docking, pharmacophore based virtual screening and molecular dynamics studies towards the identification of potential leads for the management of .

Damale M, Patil R, Ansari S, Alkahtani H, Almehizia A, Shinde D RSC Adv. 2022; 9(45):26176-26208.

PMID: 35531003 PMC: 9070323. DOI: 10.1039/c9ra03281a.

References

Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J . Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer.... Am J Gastroenterol. 2003; 98(3):562-7. DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x. View

de Boer W, Driessen W, Potters V, Tytgat G . Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol. 1994; 89(11):1993-7. View

Megraud F, Lamouliatte H . Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003; 17(11):1333-43. DOI: 10.1046/j.1365-2036.2003.01592.x. View

BADER J . The safety profile of De-Nol. Digestion. 1987; 37 Suppl 2:53-9. DOI: 10.1159/000199559. View

Gisbert J, Calvet X, OConnor A, Megraud F, OMorain C . Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010; 44(5):313-25. DOI: 10.1097/MCG.0b013e3181c8a1a3. View

Marshall B, Goodwin C, Warren J, Murray R, Blincow E, Blackbourn S . Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988; 2(8626-8627):1437-42. DOI: 10.1016/s0140-6736(88)90929-4. View

Treiber G, Ammon S, Schneider E, Klotz U . Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter. 1998; 3(1):54-8. DOI: 10.1046/j.1523-5378.1998.08019.x. View

Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl A . Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2012; 62(1):34-42. DOI: 10.1136/gutjnl-2012-302254. View

Romano M, Cuomo A, Gravina A, Miranda A, Iovene M, Tiso A . Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010; 59(11):1465-70. DOI: 10.1136/gut.2010.215350. View

10.

Luther J, Higgins P, Schoenfeld P, Moayyedi P, Vakil N, Chey W . Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2009; 105(1):65-73. DOI: 10.1038/ajg.2009.508. View

11.

Bazzoli F, Zagari M, Pozzato P, Varoli O, Fossi S, Ricciardiello L . Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 1998; 12(5):439-45. DOI: 10.1046/j.1365-2036.1998.00330.x. View

12.

Ford A, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P . Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008; 14(48):7361-70. PMC: 2778120. DOI: 10.3748/wjg.14.7361. View

13.

Essa A, Kramer J, Graham D, Treiber G . Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009; 14(2):109-18. PMC: 2840655. DOI: 10.1111/j.1523-5378.2009.00671.x. View

14.

Borody T, Carrick J, Hazell S . Symptoms improve after the eradication of gastric Campylobacter pyloridis. Med J Aust. 1987; 146(8):450-1. DOI: 10.5694/j.1326-5377.1987.tb120344.x. View

15.

. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994; 272(1):65-9. View

16.

Hillemand P, PALLIERE M, Laquais B, Bouvet P . [Bismuth treatment and blood bismuth levels]. Sem Hop. 1977; 53(31-32):1663-9. View

17.

. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut. 1997; 41(1):8-13. PMC: 1027220. DOI: 10.1136/gut.41.1.8. View

18.

Fuccio L, Minardi M, Zagari R, Grilli D, Magrini N, Bazzoli F . Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007; 147(8):553-62. DOI: 10.7326/0003-4819-147-8-200710160-00008. View

19.

Schabereiter-Gurtner C, Hirschl A, Dragosics B, Hufnagl P, Puz S, Kovach Z . Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J Clin Microbiol. 2004; 42(10):4512-8. PMC: 522301. DOI: 10.1128/JCM.42.10.4512-4518.2004. View

20.

Russmann H, Adler K, Haas R, Gebert B, Koletzko S, Heesemann J . Rapid and accurate determination of genotypic clarithromycin resistance in cultured Helicobacter pylori by fluorescent in situ hybridization. J Clin Microbiol. 2001; 39(11):4142-4. PMC: 88500. DOI: 10.1128/JCM.39.11.4142-4144.2001. View